Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors

NCT06253130 is registered in ClinicalTrials.gov with Eikon Therapeutics as lead sponsor.

NCT NCT06253130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06253130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors
Lead sponsor
Eikon Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 11, 2023
Completion date
December 1, 2027
Enrollment
156 (estimated)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor